

Product Number

**926-08446**

Storage: -20°C  
prior to reconstitution;  
4°C after reconstitution

Revised: May 2011

Updates available at:

<http://biosupport.licor.com>

**Limitation of Liability and  
Limited Use Label License**

LI-COR IRDye® Infrared Dyes and reagent products are offered for research purposes only and are not intended for human therapeutic or diagnostic use. The purchase of this product conveys to the buyer the non-transferable right to use the amount of product purchased and the components of the product in research conducted by the buyer (whether the buyer is a not-for-profit, academic or for-profit entity). The buyer shall not sell or otherwise transfer this product, its components, or materials made there from to any third party. Buyer shall not use this product or its components for commercial purposes. The term "commercial purposes" shall mean any activity by a party for consideration and may include, but is not limited to, use of the product or its components (i) in manufacturing, (ii) to provide a service, information or data, (iii) for therapeutic, diagnostic or prophylactic purposes, or (iv) for resale, whether or not such product or its components are resold for use in research. The use of this product by the buyer constitutes agreement with the terms of this limited use label license for LI-COR IRDye infrared dyes and reagent products. Inquiries regarding the licensing of one or more IRDye infrared dyes should be submitted by e-mail to busdev@licor.com.

LI-COR BIOSCIENCES DOES NOT PROVIDE RESEARCH ADVICE OR DETERMINE OR RECOMMEND ANY POTENTIAL USES FOR IRDYE INFRARED DYES AND REAGENT PRODUCTS. LI-COR BIOSCIENCES MAKES NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER INCLUDING, BUT NOT LIMITED TO, WARRANTY OF FITNESS FOR PURPOSE, OR MERCHANTABILITY OR RESULTS OBTAINED FROM USE OF IRDYE INFRARED DYES. IN NO EVENT SHALL LI-COR BE LIABLE FOR LOST PROFITS, CONSEQUENTIAL, EXEMPLARY, SPECIAL, DIRECT, INCIDENTAL, OR PUNITIVE DAMAGES, OR ATTORNEY FEES, EVEN IF LI-COR HAD BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN, OF THE POSSIBILITIES THEREOF. NO EMPLOYEE, AGENT OR REPRESENTATIVE OF LI-COR HAS THE AUTHORITY TO BIND LI-COR TO ANY ORAL REPRESENTATION OR WARRANTY EXCEPT AS SPECIFICALLY SET FORTH HEREIN.

© 2011 LI-COR, Inc. LI-COR is an ISO 9001 registered company. LI-COR, Odyssey, Pearl, BrightSite, MousePOD, IRDye, and BoneTag are trademarks and registered trademarks of LI-COR, Inc., in the United States and other countries. The Odyssey Infrared Imager, Pearl Imager, IRDye 800CW and IRDye reagents are covered by U.S. and foreign patents and patents pending.

Doc #988-12108

**LI-COR®**

Biosciences

4647 Superior Street • P.O. Box 4000  
Lincoln, Nebraska 68504 USA  
North America: 800-645-4267  
International: 402-467-0700  
FAX: 402-467-0819

LI-COR GmbH Germany, Serving Europe,  
Middle East and Africa: +49 (0) 6172 17 17 771  
LI-COR UK Ltd. UK, Serving UK, Ireland, and  
Scandinavia: +44 (0) 1223 422104  
All other countries, contact LI-COR Biosciences  
or a local LI-COR distributor:  
[Http://www.licor.com/distributors](http://www.licor.com/distributors)

[www.licor.com](http://www.licor.com)

**BrightSite™**  
Small Animal Imaging Agents

## IRDye® 800CW EGF Optical Probe

IRDye 800CW EGF Optical Probe is a near-infrared labeled, recombinant human epidermal growth factor. It can be used as an optical tracking agent for *in vitro*, *in vivo*, whole organ, and tissue section analysis, allowing the same probe to be used in all steps of the discovery process.

## Description

Epidermal growth factor (EGF) is a polypeptide containing 54 amino acid residues (molecular weight = 6.2 kDa). EGF stimulates differentiation and proliferation of epithelial cells. Binding of EGF to the EGF receptor (EGFR) stimulates mitogenic activity and has proven effective in both *in vitro* and *in vivo* assays when monitoring specific solid tumor models that exhibit over-expression of EGFR<sup>1-5</sup>.

## Material

IRDye 800CW EGF Optical Probe solution was passed through a 0.2 µm nylon membrane into a sterile polypropylene tube and then lyophilized. The product is supplied as a lyophilized powder from phosphate-buffered saline (PBS), pH 7.2. The recommended individual dose per mouse (~25 grams) is 1 nmole. Each tube contains 20 nmole of IRDye 800CW EGF Optical Probe.

## Properties (in 1X PBS)

- Absorption maximum: 779 nm
- Emission maximum: 795 nm
- Appearance: Lyophilized pellet

## Storage and Handling

Upon receipt, immediately store at -20°C prior to reconstitution. When stored properly, this product is stable in the lyophilized state for 3 months. After reconstitution, store at 4°C. Reconstituted material should be used within 2 weeks. **Protect from light.**

## Directions for Use

- Reconstitute material in 1.5 ml of sterile 1x PBS for a final concentration of 1.33 nmole per 100 µl. To ensure sterility, filter through a 0.2 µm nylon membrane.
- Recommended administration: Inject 1 nmole intravenously via tail vein.
- *In vivo* Imaging: Optimal signal-to-noise ratios occur 3-4 days post injection; however, this may vary for each tumor model system used.
- Clearance: In a tumor-negative animal (NOD/SCID mouse), there is greater than 90% whole body clearance in 24 hours post injection.

## Precautions

The probe is processed through the liver and kidneys with excretion via the bladder, which may increase background when imaging in the abdominal region.

**Continued**

## References

1. J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat and G. Milano. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. *Annals of Oncology*, 16: 189-194, 2005.
2. Amir Onn, Arlene M. Correa, Michael Gilcrease, Takeshi Isobe, Erminia Massarelli, Corazon D. Bucana, Michael S. O'Reilly, Waun K. Hong, Isaiah J. Fidler, Joe B. Putnam, and Roy S. Herbst. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage 1 non-small cell lung cancer. *Clinical Cancer Research*, 10: 136-143, 2004.
3. Konstantin Sokolov, Michele Follen, Jesse Aaron, Ina Pavlova, Anais Malpica, Reuben Lotan, and Rebecca Richards-Kortum. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. *Cancer Research*, 63: 1999-2004, 2003.
4. Shi Ke, Xiaoxia Wen, Michael Gurfinkel, Chusilp Charnsangavej, Sidney Wallace, Eva M. Sevick-Muraca, and Chun Li. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. *Cancer Research*, 63: 7870-7875, 2003.
5. Arnab Chakravarti, Meaghan A. Delaney, Elizabeth Noll, Peter McL. Black, Jay S. Loeffler, Alona Muzikansky, and Nicholas J. Dyson. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. *Clinical Cancer Research*, 7:2387-2395, 2001.
6. C. S. Kearns. Immunofluorescent mapping of Cannabinoid CB1 and dopamine D2 receptors in the mouse brain. LI-COR Biosciences, 2004.